EffRx to Showcase Binosto® at the Virtual WCO-IOF-ESCEO 2020 Congress

EffRx Pharmaceuticals SA is proud to announce that it will participate in the 20th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, starting on the 20th of August 2020. The WCO-IOF-ESCEO Congress is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to showcase its flagship product Binosto®, the only buffered soluble alendronate for the treatment of postmenopausal osteoporosis.

EffRx Pharmaceuticals SA is also pleased to inform that a study on the cost-effectiveness of Binosto® will be presented at the WCO-IOF-ESCEO Congress. The data will be presented by Professor M. Hiligsmann in an oral communication (OC40) entitled, “COST-EFFECTIVENESS OF BINOSTO (BUFFERED SOLUBLE ALENDRONATE 70 MG) EFFERVESCENT TABLET FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN ITALY.”

The authors of the cost-effectiveness study conclude that Binosto® represents a cost-effective strategy compared with generic alendronate, zoledronic acid and no treatment, and a dominant strategy compared to denosumab for the treatment of postmenopausal women with osteoporosis in Italy aged 60 years and over.

Medical professionals from around the world will be able to learn more about Binosto® and its exciting properties at the Binosto® virtual booth.

About EffRx Pharmaceuticals SA

EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.

About Binosto®/Steovess®

Our lead commercialized product Binosto® is indicated for the treatment of osteoporosis and marketed in US, Europe and Asia. Binosto® (alendronate 70 mg effervescent tablets) is the first and only buffered solution for the treatment of postmenopausal osteoporosis. It reduces the risk of hip, spine, and non-spine fractures.1 The buffered solution with high acid-neutralizing capacity minimizes the risk of exposing the esophagus (in case of reflux) and the stomach to acidified alendronate.2,3 Binosto® is taken once a week as an easy-to-swallow, buffered solution with no risk of a tablet getting lodged in the esophagus. Binosto® has the potential to improve adherence to therapy4, thereby decreasing the risk of disabling fractures.

Disclaimer

Please refer to the official Binosto®/Steovess® prescribing information and approved indications, contraindications, and warnings in your country.

References:

  1. Black DM et al. Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-4124.
  2. Binosto Summary of Product Characteristics. 2019.
  3. Hodges LA et al. Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronate. Int J Pharm 2012;432:57-62.
  4. Giusti A et al. Persistence with Buffered Solution of Alendronate 70mg: Prospective Observational Study. J Bone Miner Res 2018;33(S1):S174-S175.